Allogene Reports Results of ALLO-501 and ALLO-501A in P-I Studies for Relapsed/Refractory Non-Hodgkin Lymphoma

 Allogene Reports Results of ALLO-501 and ALLO-501A in P-I Studies for Relapsed/Refractory Non-Hodgkin Lymphoma

Allogene Reports Results of ALLO-501 and ALLO-501A in P-I Studies for Relapsed/Refractory Non-Hodgkin Lymphoma

Shots:

  • The P-I ALPHA study of ALLO-501 produced durable CR with the longest ongoing CR @15mos. in both LBCL and FL. ORR (75%) and CR (50%) across histologies in CAR T naïve patients, on par with data from pivotal trials of autologous CAR T therapies
  • The APLHA-2 data demonstrated comparable efficacy & safety for ALLO-501A relative to ALLO-501. The consolidation dosing was well tolerated and showed early promise with 4 patients converting from PR to CR following the second dose of ALLO-501 or ALLO-501A
  • The data will be presented at ASCO 2021. The company plan to initiate the pivotal trial of ALLO-501A in late 2021

Click here to­ read full press release/ article | Ref: Allogene | Image: Allogene

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post